STAT+: Asthma drug from Amgen, AstraZeneca achieves main goals in late-stage clinical trial

An experimental medicine from AstraZeneca and Amgen significantly reduced the frequency of asthma attacks when added to standard treatment, achieving the goals of a late-stage clinical trial.

Click to view original post